PL4217007T3 - Koniugaty peptydowe sn38 przydatne w leczeniu nowotworu - Google Patents
Koniugaty peptydowe sn38 przydatne w leczeniu nowotworuInfo
- Publication number
- PL4217007T3 PL4217007T3 PL21783267.4T PL21783267T PL4217007T3 PL 4217007 T3 PL4217007 T3 PL 4217007T3 PL 21783267 T PL21783267 T PL 21783267T PL 4217007 T3 PL4217007 T3 PL 4217007T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer
- useful
- treatment
- peptidic conjugates
- peptidic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382854 | 2020-09-28 | ||
| PCT/EP2021/076546 WO2022064052A1 (en) | 2020-09-28 | 2021-09-27 | Peptidic conjugates of sn38 useful in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4217007T3 true PL4217007T3 (pl) | 2025-03-17 |
Family
ID=72709321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21783267.4T PL4217007T3 (pl) | 2020-09-28 | 2021-09-27 | Koniugaty peptydowe sn38 przydatne w leczeniu nowotworu |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240285784A1 (pl) |
| EP (1) | EP4217007B9 (pl) |
| JP (1) | JP2023542382A (pl) |
| CN (1) | CN116406301B (pl) |
| AU (1) | AU2021347611A1 (pl) |
| CA (1) | CA3193485A1 (pl) |
| ES (1) | ES3010582T3 (pl) |
| IL (1) | IL301558B1 (pl) |
| PL (1) | PL4217007T3 (pl) |
| WO (1) | WO2022064052A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315988A (en) * | 2022-03-28 | 2024-11-01 | Sant Joan De Deu Hospital | Peptidic water-soluble delivery system of anticancer drugs |
| AU2023317659A1 (en) * | 2022-08-01 | 2025-02-27 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Site-specific modification by a bbb-shuttle of antibody-based entities for crossing the blood-brain barrier |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| EP1998809B1 (en) | 2006-03-30 | 2014-06-25 | Drais Pharmaceuticals, Inc. | Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same |
| WO2015001015A1 (en) | 2013-07-04 | 2015-01-08 | Universitat De Barcelona | Actively transported and protease-resistant peptides as bbb shuttles and shuttle-cargo constructs |
| CN106061483B (zh) | 2013-10-04 | 2021-01-08 | 普洛林克斯有限责任公司 | Sn-38的缓释结合物 |
| CN110177566A (zh) * | 2016-09-30 | 2019-08-27 | 伊夫7治疗公司 | 用于制备靶向肿瘤-脉管系统的抗肿瘤剂的方法 |
| IL315988A (en) * | 2022-03-28 | 2024-11-01 | Sant Joan De Deu Hospital | Peptidic water-soluble delivery system of anticancer drugs |
-
2021
- 2021-09-27 ES ES21783267T patent/ES3010582T3/es active Active
- 2021-09-27 CA CA3193485A patent/CA3193485A1/en active Pending
- 2021-09-27 WO PCT/EP2021/076546 patent/WO2022064052A1/en not_active Ceased
- 2021-09-27 CN CN202180066590.6A patent/CN116406301B/zh active Active
- 2021-09-27 JP JP2023518802A patent/JP2023542382A/ja active Pending
- 2021-09-27 US US18/028,515 patent/US20240285784A1/en active Pending
- 2021-09-27 IL IL301558A patent/IL301558B1/en unknown
- 2021-09-27 AU AU2021347611A patent/AU2021347611A1/en active Pending
- 2021-09-27 PL PL21783267.4T patent/PL4217007T3/pl unknown
- 2021-09-27 EP EP21783267.4A patent/EP4217007B9/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN116406301B (zh) | 2026-04-14 |
| WO2022064052A1 (en) | 2022-03-31 |
| AU2021347611A9 (en) | 2025-04-10 |
| IL301558A (en) | 2023-05-01 |
| EP4217007C0 (en) | 2024-11-06 |
| CN116406301A (zh) | 2023-07-07 |
| US20240285784A1 (en) | 2024-08-29 |
| EP4217007A1 (en) | 2023-08-02 |
| CA3193485A1 (en) | 2022-03-31 |
| EP4217007B1 (en) | 2024-11-06 |
| EP4217007B9 (en) | 2025-01-15 |
| IL301558B1 (en) | 2026-08-01 |
| JP2023542382A (ja) | 2023-10-06 |
| ES3010582T3 (en) | 2025-04-03 |
| AU2021347611A1 (en) | 2023-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288485B2 (en) | Anti-TROP2 antibody conjugates - a drug for use in cancer treatment | |
| IL277854A (en) | Conjugates of antibody and drug and their use for cancer treatment | |
| IL276768A (en) | Antibody-antidrug-tissue factor conjugates and their use in cancer treatment | |
| IL287391A (en) | Antibody-drug amatoxin as an attached substance and its use | |
| IL274122A (en) | Antibody-antidrug-tissue factor conjugates and their use in cancer treatment | |
| HUE057906T2 (hu) | Kovalens kötõcsoportok ellenanyag-hatóanyag konjugátumokban és eljárások elõállításukra és alkalmazásukra | |
| IL280617A (en) | Antibody-drug conjugates against tissue factor and their use for cancer treatment | |
| IL308766A (en) | Compositions and methods for treating prostate cancer | |
| IL325918A (en) | Antibody-drug conjugates for use in the treatment of metastatic brain tumor | |
| MX2021015533A (es) | Anticuerpos anti-mesotelina e inmunoconjugados de los mismos. | |
| SMT202500434T1 (it) | Sotorasib per l'uso nel trattamento del cancro | |
| IL299334A (en) | Antibody-antidrug-tissue factor conjugates and their use in cancer treatment | |
| IL281495A (en) | Quinuclidine-3-one derivatives and their use in cancer treatment | |
| EP4353320A3 (en) | Blood plasma and plasma fractions as therapy for tumor growth and progression | |
| IL291312A (en) | Anti-ptcra antibody-drug pairings and their use | |
| GB202317288D0 (en) | Pyrrolopyridone derivatives useful in the treatment of cancer | |
| IL304245A (en) | Phospholipid-flaveglin conjugates and methods of using them for targeted cancer treatment | |
| EP4486344A4 (en) | ORAL PCLX-001 IN THE TREATMENT OF CANCER IN HUMANS | |
| IL309249A (en) | Conjugates including phosphoantigens and their use in therapy | |
| EP4217007C0 (en) | SN38 PEPTIDE CONJUGATES USEFUL FOR THE TREATMENT OF CANCER | |
| HK40045679A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| HK40037552A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| IL320603A (en) | Anti-AVB6 antibodies and anti-drug transporters and their use in cancer treatment | |
| HK40036590A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| HK40077791A (en) | Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers |